Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Price Jackson

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CTMichael S Hofman, Alicia Corlett, Cameron Pain, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 2, 2026
Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry-An FNIH Joint Academic, Clinical, and Industrial CollaborationDale L Bailey, John C Dickson, Suzanne E Lapi, et al.
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2017
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of <sup>68</sup>Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate CancerMichael S Hofman, Peter Eu, Price Jackson, et al.
Frontiers in Oncology|May 24, 2021
A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed Tomography ImagesKaushalya C Amarasinghe, Jamie Lopes, Julian Beraldo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2020
Peptide Receptor Radionuclide Therapy with <sup>67</sup>Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor ModelCarleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJohn Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2026
Thrombotic Microangiopathy in Patients Treated with <sup>177</sup>Lu-PSMA Combination TherapiesJoanna C Chan, Mitchell T Carroll, Nadia Hitchen, et al.
The Lancet. Oncology|May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyMichael S Hofman, John Violet, Rodney J Hicks, et al.
European Urology Focus|November 11, 2020
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of <sup>177</sup>Lu-PSMA-617 Prior to ProstatectomyNattakorn Dhiantravan, John Violet, Renu Eapen, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CTMichael S Hofman, Alicia Corlett, Cameron Pain, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 2, 2026
Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry-An FNIH Joint Academic, Clinical, and Industrial CollaborationDale L Bailey, John C Dickson, Suzanne E Lapi, et al.
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2017
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of <sup>68</sup>Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate CancerMichael S Hofman, Peter Eu, Price Jackson, et al.
Frontiers in Oncology|May 24, 2021
A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed Tomography ImagesKaushalya C Amarasinghe, Jamie Lopes, Julian Beraldo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2020
Peptide Receptor Radionuclide Therapy with <sup>67</sup>Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor ModelCarleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJohn Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2026
Thrombotic Microangiopathy in Patients Treated with <sup>177</sup>Lu-PSMA Combination TherapiesJoanna C Chan, Mitchell T Carroll, Nadia Hitchen, et al.
The Lancet. Oncology|May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyMichael S Hofman, John Violet, Rodney J Hicks, et al.
European Urology Focus|November 11, 2020
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of <sup>177</sup>Lu-PSMA-617 Prior to ProstatectomyNattakorn Dhiantravan, John Violet, Renu Eapen, et al.
Pageof 5